IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: As STAT3 KO eliminates the pro-inflammatory IL-6 signature necessary for the maintenance of CML disease burden [26], it precluded our ability to use a genetic loss of STAT3 for studying IM-persistent LSCs.